These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18927431)

  • 121. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.
    Hatzi K; Melnick A
    Trends Mol Med; 2014 Jun; 20(6):343-52. PubMed ID: 24698494
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Roles of BCL6 in normal and transformed germinal center B cells.
    Basso K; Dalla-Favera R
    Immunol Rev; 2012 May; 247(1):172-83. PubMed ID: 22500840
    [TBL] [Abstract][Full Text] [Related]  

  • 123. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
    Hurtz C; Hatzi K; Cerchietti L; Braig M; Park E; Kim YM; Herzog S; Ramezani-Rad P; Jumaa H; Müller MC; Hofmann WK; Hochhaus A; Ye BH; Agarwal A; Druker BJ; Shah NP; Melnick AM; Müschen M
    J Exp Med; 2011 Oct; 208(11):2163-74. PubMed ID: 21911423
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.
    Green MR; Vicente-Dueñas C; Romero-Camarero I; Long Liu C; Dai B; González-Herrero I; García-Ramírez I; Alonso-Escudero E; Iqbal J; Chan WC; Campos-Sanchez E; Orfao A; Pintado B; Flores T; Blanco O; Jiménez R; Martínez-Climent JA; Criado FJ; Cenador MB; Zhao S; Natkunam Y; Lossos IS; Majeti R; Melnick A; Cobaleda C; Alizadeh AA; Sánchez-García I
    Nat Commun; 2014 Jun; 5():3904. PubMed ID: 24887457
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
    Kaida M; Morita-Hoshi Y; Soeda A; Wakeda T; Yamaki Y; Kojima Y; Ueno H; Kondo S; Morizane C; Ikeda M; Okusaka T; Takaue Y; Heike Y
    J Immunother; 2011 Jan; 34(1):92-9. PubMed ID: 21150717
    [TBL] [Abstract][Full Text] [Related]  

  • 126. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
    Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
    Nat Med; 2009 Dec; 15(12):1369-76. PubMed ID: 19966776
    [TBL] [Abstract][Full Text] [Related]  

  • 127. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.
    Ci W; Polo JM; Cerchietti L; Shaknovich R; Wang L; Yang SN; Ye K; Farinha P; Horsman DE; Gascoyne RD; Elemento O; Melnick A
    Blood; 2009 May; 113(22):5536-48. PubMed ID: 19307668
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
    Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
    Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship.
    Sakamoto K; Sogabe S; Kamada Y; Sakai N; Asano K; Yoshimatsu M; Ida K; Imaeda Y; Sakamoto JI
    Biochem Biophys Res Commun; 2017 Jan; 482(2):310-316. PubMed ID: 27856253
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 131. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
    Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
    Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
    [TBL] [Abstract][Full Text] [Related]  

  • 132. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Bcl6 drives stem-like memory macrophages differentiation to foster tumor progression.
    Zhang W; Han Q; Ding Y; Zhou H; Chen Z; Wang J; Xiang J; Song Z; Abbas M; Shi L
    Cell Mol Life Sci; 2022 Dec; 80(1):14. PubMed ID: 36542153
    [TBL] [Abstract][Full Text] [Related]  

  • 134. TBL1X: At the crossroads of transcriptional and posttranscriptional regulation.
    Pray BA; Youssef Y; Alinari L
    Exp Hematol; 2022 Dec; 116():18-25. PubMed ID: 36206873
    [TBL] [Abstract][Full Text] [Related]  

  • 135. B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
    McLachlan T; Matthews WC; Jackson ER; Staudt DE; Douglas AM; Findlay IJ; Persson ML; Duchatel RJ; Mannan A; Germon ZP; Dun MD
    Mol Cancer Res; 2022 Dec; 20(12):1711-1723. PubMed ID: 36166198
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Novel API Coated Catheter Removes Amyloid-β from Plasma of Patients with Alzheimer's Disease.
    Chhipa RR; Gandbhir O; Le H; Sankar S; Sundaram P
    HSOA J Alzheimers Neurodegener Dis; 2021; 7(1):. PubMed ID: 34825129
    [TBL] [Abstract][Full Text] [Related]  

  • 137. An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach.
    Yanguas-Casás N; Pedrosa L; Fernández-Miranda I; Sánchez-Beato M
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207773
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
    Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
    J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
    [TBL] [Abstract][Full Text] [Related]  

  • 139. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
    Guo J; Liu Y; Lv J; Zou B; Chen Z; Li K; Feng J; Cai Z; Wei L; Liu M; Pang X
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393503
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.